GlassScriptPhysician profile
Daniel Thomas Kraus
NPI 1184496937
$11,671.49
in general payments reported to CMS, 2019-2025
29 companies · $6,357 in 2025
The $6,357 reported for 2025 was more than what 99% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $550 · 2024: $4,765 · 2025: $6,357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Travel and Lodging: $1,257 · Education: $10.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,403.86 |
| Travel and Lodging | $1,257.03 |
| Education | $10.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,447.30 | 2023-2025 | |
| Amgen INC. | $2,110.52 | 2023-2025 | Krystexxa, Otezla, Enbrel |
| Takeda Pharmaceuticals U.S.A., INC. | $1,650.90 | 2025 | |
| Ucb, INC. | $1,485.15 | 2023-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $762.37 | 2023-2025 | Tremfya |
| Pfizer INC. | $648.90 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $485.27 | 2024-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $323.81 | 2023-2025 | Saphnelo |
| Radius Health, INC. | $271.35 | 2024-2025 | Tymlos |
| Lilly USA, LLC | $216.77 | 2024-2025 | Taltz |
| Organon LLC | $195.15 | 2023-2025 | Renflexis, Hadlima, Nexplanon |
| Glaxosmithkline, LLC. | $178.84 | 2024 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $154.72 | 2024-2025 | Orencia |
| Genzyme Corporation | $107.97 | 2024-2025 | |
| Octapharma USA, INC. | $89.67 | 2024-2025 | Octagam Immune Globulin (Human) |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $62.62 | 2025 | |
| Sobi, INC | $56.59 | 2024-2025 | |
| Sandoz INC. | $54.65 | 2023-2025 | Hyrimoz |
| Genentech USA, INC. | $54.05 | 2024 | Actemra |
| Ani Pharmaceuticals, INC. | $39.93 | 2025 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $38.06 | 2025 | Strensiq |
| Actelion Pharmaceuticals US, INC. | $36.63 | 2023-2024 | Opsumit, Uptravi |
| Kiniksa Pharmaceuticals International, Plc | $36.51 | 2024 | Arcalyst |
| Ferring Pharmaceuticals INC. | $35.11 | 2024 | Euflexxa |
| Scilex Pharmaceuticals INC. | $33.00 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $29.27 | 2024 | Truxima |
| Aurinia Pharma U.S., INC. | $28.46 | 2024 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.86 | 2025 | Jascayd |
| Horizon Therapeutics Plc | $18.06 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kraus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.